-+ 0.00%
-+ 0.00%
-+ 0.00%
MetaVia Completes Last Patient Visit In Extended 24-Week Phase 1 Part 3A Study Of DA-1726
Share
Listen to the news

Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending